The bill specifies that 'approved clinical trials' encompass those in phases I to IV that focus on the prevention, detection, or treatment of life-threatening conditions. It also outlines that routine care costs include medically necessary services linked to the evaluation method being tested in the trial, including services addressing complications arising from both the medical treatment and clinical trial participation. As such, this bill could significantly enhance the willingness of patients to engage in clinical research, knowing that essential care services related to their treatments will be financially covered.
House Bill 2438, introduced by Rep. Camille Y. Lilly, amends the Medical Assistance Article of the Illinois Public Aid Code to require the medical assistance program to cover routine care costs associated with approved clinical trials. This coverage applies when the same routine care costs are typically covered even when not incurred during a clinical trial. It aims to increase patient access to cutting-edge treatments by alleviating financial burdens associated with routine care during these trials, particularly for patients with life-threatening diseases such as cancer.
Notably, the bill seeks to strike a balance between the need for innovative treatments in medical research and the financial risks associated with clinical trial participation. It may face discussions around cost implications for the medical assistance program and whether participants should have to share in these costs if they are deemed to receive enhanced care through experimental trials. The precise definition of 'routine care costs' is substantial, as it excludes items that are typically provided for research purposes or solely for eligibility assessment, which could spark debate regarding what is covered under patient care.